1. From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis
Ann Intern Med. 1999;130(10): doi: /
Figure Legend:
Results of multivariate sensitivity analysis.circlesdiamondstrianglesQALYEach solid line indicates the incremental cost-effectiveness of inpatient treatment with low-molecular-weight heparin relative to unfractionated heparin at various levels of pharmacy costs for low-molecular-weight heparin. The middle line ( ) represents baseline assumptions about the effectiveness of low-molecular-weight heparin in preventing early complications. The upper ( ) and lower ( ) lines represent the incremental cost-effectiveness of low-molecular-weight heparin treatment at its lower and upper limits of effectiveness in preventing early complications. Vertical bars represent the effect of varying the cost of treating early complications by ±25%. A negative cost-effectiveness ratio indicates that low-molecular-weight heparin is a cost-saving strategy. The cost-effectiveness ratio for inpatient treatment with low-molecular-weight heparin was almost always less than $ per quality-adjusted life-year ( ) except when low-molecular-weight heparin was assumed to be at the lower limit of effectiveness in preventing early complications and the pharmacy cost was $105 (125% of the baseline estimate) or greater.
Date of download: 1/23/2018
Copyright © American College of Physicians. All rights reserved.